Target intelligence / Profile preview

Yellow fever virus envelope glycoprotein E (YFV E)

Target
YFV E
Molecular classification
Viral envelope protein, Type II fusion protein, Other
01

Overview

The Yellow fever virus envelope glycoprotein E (commonly referred to as the YFV E protein) is the principal surface protein of the yellow fever virus, a member of the Flaviviridae family. It plays a critical role in the viral life cycle by mediating host cell attachment and subsequent membrane fusion within the endosome, which are essential steps for viral entry and infection. Structurally, the E protein is organized as a homodimer on the virion surface and consists of three distinct domains (I, II, and III). Domain III contains the primary neutralizing epitopes that interact with host cell receptors and elicit strong protective immune responses, making it the major target of neutralizing antibodies during natural infection and vaccination. Although the live-attenuated yellow fever vaccine (17D) effectively targets this protein to provide lifelong immunity, there are currently no approved direct-acting small molecule antivirals that target the E protein. However, therapeutic monoclonal antibodies, such as TY014, have been developed and evaluated in clinical trials, demonstrating the ability to neutralize the virus and prevent viremia by blocking viral attachment and membrane fusion. Other monoclonal antibodies like MBL-YFV-01 and 5A are also being investigated as potential post-exposure therapies or prophylactics.

Other names
Yellow fever virus envelope protein EYFV E proteinYellow fever virus E proteinYellow fever virus envelope glycoproteinEnvelope protein EYellow fever virus envelope proteinYFV envelope glycoprotein E
02

Mechanism of action

Inhibition of viral attachment to host cell receptors, blockade of viral membrane fusion by preventing E protein dimer-to-trimer transition, and neutralization of viral particles.

03

Biological functions

Viral membrane fusionHost cell attachmentReceptor binding for host cell entryEliciting neutralizing antibody responsesDetermining viral tissue tropism and pathogenicity
04

Disease associations

InfectionOther
05

Safety considerations

Antibody-dependent enhancement (ADE)Antigenic similarity and cross-reactivity with other flavivirusesPotential for viral mutational escape
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Anti-E protein antibodiesYFV E protein antigenViremia levels

Beyond the preview

Go deeper on Yellow fever virus envelope glycoprotein E (YFV E).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yellow fever virus envelope glycoprotein E (YFV E).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call